BioSpace News Archive

Making Sense of Engineering Titles in Biopharma

Engineers help their employers remain efficient, GMP-compliant and up-to-date on the latest technologies and industry trends.

November 28, 2023
·
4 min read
·
Charlotte LoBuono
Policy

FDA Launches Probe of Malignancies Linked to CAR-T Therapies

The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.

November 28, 2023
·
3 min read
·
Tyler Patchen
Business

BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal

Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.

November 28, 2023
·
2 min read
·
Kate Goodwin
Career Advice

Opinion: How to Vet Your Next Company

Consider each company using three different criteria: its match with the candidate’s “why,” its financial health and its employee reviews.

November 28, 2023
·
4 min read
·
Bob Broady
Policy

How Drug Prices Differ in the U.S. Versus Other Countries

The United States’ relatively high costs have become a political issue on both sides of the aisle. Here’s how international pharmaceutical prices stack up.

November 28, 2023
·
3 min read
·
Shawna Williams
Biotech Bay

Top Biopharma Companies Hiring in California Right Now

Despite recent layoffs and closures in the state, there are still many companies actively recruiting for roles in California.

November 28, 2023
·
1 min read
·
BioSpace Editorial Staff
FDA

SpringWorks Wins First FDA Approval for Non-Cancerous Desmoid Tumors

The Ogsiveo tablets are the first approval therapy for the rare subtype of soft tissue sarcomas, which can lead to severe pain and disability and previously were treated primarily through surgery.

November 28, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Acelyrin Flags CRO Errors in Izokibep Program After Late-Stage Failure

The biotech blames contract research organization Fortrea for incorrectly coding the dosing sequence in a psoriatic arthritis trial, which it contends resulted in some patients being given the wrong treatments.

November 28, 2023
·
2 min read
·
Tristan Manalac
Policy

FDA Rejects Aldeyra’s Dry Eye Drug, Cites Need for Additional Trial

Aldeyra Therapeutics is planning to run another trial, in line with the regulator’s requirements, and is expecting top-line data and a New Drug Application resubmission in the first half of 2024.

November 28, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Argenx’s Vyvgart Fails to Hit Primary, Secondary Endpoints in Phase III Trial

The Dutch biotech’s stock dropped about 10% Tuesday morning after the company reported that its injectable Vyvgart Hytrulo missed the primary and secondary endpoints in an immune thrombocytopenia study.

November 28, 2023
·
2 min read
·
Tyler Patchen